Ameriprise’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$621K Buy
+110,852
New +$695K ﹤0.01% 3635
2026
Q1
– Sell
-34,120
Closed -$306K – 4177
2025
Q4
$306K Buy
34,120
+20
+0.1% +$124 ﹤0.01% 3800
2025
Q3
$126K Buy
+34,100
New +$92.9K ﹤0.01% 3957
2024
Q3
– Sell
-234,030
Closed -$683K – 3984
2024
Q2
$683K Hold
234,030
– – ﹤0.01% 3328
2024
Q1
$852K Buy
234,030
+159,802
+215% +$307K ﹤0.01% 3230
2023
Q4
$112K Buy
74,228
+26,284
+55% +$33.8K ﹤0.01% 3804
2023
Q3
$64.2K Buy
47,944
+24,524
+105% +$40.8K ﹤0.01% 3826
2023
Q2
$42.2K Buy
+23,420
New +$39.8K ﹤0.01% 3871
2022
Q1
– Sell
-727,956
Closed -$6.19M – 3999
2021
Q4
$6.19M Buy
727,956
+120
+0% +$1.1K ﹤0.01% 2318
2021
Q3
$7.24M Hold
727,836
– – ﹤0.01% 2118
2021
Q2
$6.78M Hold
727,836
– – ﹤0.01% 2235
2021
Q1
$7.61M Buy
+727,836
New +$8.14M ﹤0.01% 2089

Other funds holding NUVB

Ameriprise's NUVB Position: Q3 2026 in Review

Ameriprise opened a new position in Nuvation Bio (NUVB) in Q3 2026: 110,852 shares worth $621K. The stake represents ﹤0.01% of the portfolio and ranks #3635 among its holdings. This is a return to the name: Ameriprise previously reported a position in NUVB as recently as Q4 2025.

Ameriprise first reported a position in NUVB in Q1 2021 and has held it in 12 quarters since. The position peaked at $7.61M in Q1 2021. 260 funds tracked by Wall St. Rank hold NUVB as of Q3 2026.

  • Ameriprise held 110,852 shares of Nuvation Bio worth $621K as of Q3 2026.
  • Nuvation Bio was a new Ameriprise position in Q3 2026.
  • Nuvation Bio made up ﹤0.01% of Ameriprise's portfolio in Q3 2026, its #3635 holding.
  • Ameriprise first reported a position in Nuvation Bio in Q1 2021 and has held it in 12 quarters since.
  • Ameriprise's Nuvation Bio position peaked at $7.61M in Q1 2021.
  • 260 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2026.

Based on Ameriprise's 13F filing for Q3 2026, filed 16 Nov 2026.